Mr. Oren Shuster reports

IMC GERMANY ANNOUNCES OUTSTANDING PRELIMINARY Q3, 2024 PERFORMANCE WITH 50% GROWTH OVER Q2

IM Cannabis Corp.' preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH, for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50-per-cent increase in revenue compared with the second quarter, where IMC Germany sold about $3.5-million. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products.

Since the partial legalization of cannabis in Germany came into effect in April, 2024, the demand for cannabis products in pharmacies has increased significantly, emphasizing the importance of a robust, reliable supply chain.

"Since April 1, one of our key objectives was to ensure a supply chain strong enough to meet the increase in demand. This preliminary 50-per-cent growth is testament, in part, to delivering on this objective," said Oren Shuster, chief executive officer of IM. "We are thrilled with our Q3 performance, which not only surpassed our own targets but also highlights the dedication and hard work of our entire team."

About IM Cannabis Corp.

IM is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company has focused its resources to achieve sustainable and profitable growth in its highest-value markets, Israel and Germany. The company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies, on-line platforms, distribution centres and logistical hubs in Israel that enable the safe delivery and quality control of IM products throughout the entire value chain. In Germany, the IM ecosystem operates through Adjupharm, where it distributes cannabis to pharmacies for medical cannabis patients.

We seek Safe Harbor.